Research area
Metabolic and incretin
Compounds studied for effects on blood sugar, appetite, and body weight through incretin and related metabolic pathways -- the family that includes GLP-1 receptor agonists and the newer multi-receptor agonists behind the current wave of weight-loss drug development.
36 entries in this category.
-
5-Amino-1MQ
5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide, studied so far only in mice and rats. Diet-induced-obese mice showed reduced weight and fat mass, and aged mice showed improved muscle regeneration and grip strength, but no interventional trial, observational study or case report of the compound in a human being has been located anywhere.
-
Adipotide
Adipotide (FTPP / Prohibitin-TP01) is a peptide designed to destroy the blood vessels feeding white fat, producing rapid weight loss in obese mice and rhesus monkeys. Its only human test was a small, terminated Phase I cancer trial with no published results, it identified a kidney-function safety signal in primates, and it is not approved or available as an obesity treatment.
-
Aleniglipron (GSBR-1290)
Investigational compound This compound is not approved for any use. Evidence for aleniglipron comes from Structure Therapeutics’ own published and presented clinical trial data. Aleniglipron (development code GSBR-1290) is an investigational once-daily oral, small-molecule GLP-1 receptor agonist from Structure Therapeutics, being developed for obesity and overweight with weight-related comorbidities. Unlike injectable GLP-1 peptides, it is ... <a title="Berobenatide" class="read-more" href="https://peptideblog.net/peptides/berobenatide/" aria-label="Read more about Berobenatide">Read more</a>
-
Amycretin
Amycretin is Novo Nordisk's experimental dual GLP-1/amylin receptor agonist for weight loss and type 2 diabetes, with published phase 1b/2a human data showing up to 22% weight loss. Not approved anywhere; phase 3 trials are under way, including AMAZE 9 for the oral tablet.
-
AOD-9604
Every human trial of AOD-9604 was oral or intravenous. None was subcutaneous, which is the only route anyone uses, and the near-universal figure of 300 micrograms injected daily sits between the two lowest oral tablet doses of the 24 week study that ended the programme, a study that failed. Six randomised trials in around 900 people found it did not raise IGF-1 or disturb glucose, and never met an efficacy endpoint.
-
ATX-304
ATX-304 (O-304) is a small-molecule pan-AMPK activator, not a peptide, from Betagenon AB and now Amplifier Therapeutics (Cambrian Bio). A peer-reviewed 2018 Phase IIa (65 adults, 1,000 mg a day for 28 days) showed a modest fall in fasting glucose. A June 2026 conference abstract on a Phase 1b (23 adults, 400 mg a day by mouth) reported a higher resting metabolic rate. Investigational and not approved.
-
BAM15
Also relevant to longevity and mitochondrial research. BAM15 is a non-peptide mitochondrial uncoupler that reversed diet-induced obesity and insulin resistance in mice without observed toxicity, but it has never been tested in humans. It shares its basic mechanism with DNP, a chemical with a documented history of fatal overheating deaths, and no human dose has ever been established.
* Also filed under: Longevity and mitochondrial
-
Berobenatide
Berobenatide (MET-097i, PF-08653944) is an experimental GLP-1 receptor agonist built for once-monthly use, developed by Metsera and now owned by Pfizer. Sponsor-reported Phase 2b results show up to 12.3% placebo-adjusted weight loss at week 28.
-
Brenipatide
Brenipatide (LY3537031) is Eli Lilly's investigational GIP/GLP-1 receptor agonist in phase 3 trials for alcohol use disorder and major depressive disorder, not weight loss. Phase 1 data showed GI side effects matching placebo. Not approved anywhere.
-
Cagri-Sema
CagriSema is Novo Nordisk's investigational combination of cagrilintide and semaglutide. It produced the largest weight loss of any regimen in its own trial programme, missed the company's own guidance on the way there, and lost the only head-to-head trial against tirzepatide whose result has been announced. Vendor vials sold under the name are not a regulated product, whatever ratio they claim.
-
Cagrilintide
Cagrilintide is an investigational once-weekly amylin analogue, not approved anywhere, and it is not CagriSema. In the same phase 3 trial, REDEFINE 1, cagrilintide alone gave 11.8 percent weight loss at 68 weeks while the cagrilintide plus semaglutide combination gave 22.7 percent, so pages attributing the combination figure to cagrilintide are off by about a factor of two. It now has its own phase 3 programme, RENEW, argued on tolerability rather than potency.
-
CT-996
Quick answer: CT-996 is an investigational, once-daily oral small-molecule GLP-1 receptor agonist being developed by Roche, via its Carmot Therapeutics acquisition, for obesity and type 2 diabetes. It is a “biased” GLP-1 agonist engineered to activate one signaling pathway (cAMP) while minimizing another (beta-arrestin recruitment), a design intended to improve tolerability. In an early Phase ... <a title="Berobenatide" class="read-more" href="https://peptideblog.net/peptides/berobenatide/" aria-label="Read more about Berobenatide">Read more</a>
-
Elecoglipron (AZD5004)
Investigational, not available anywhere This compound is not approved for any use and is not currently sold by any vendor, including research-chemical and RUO (“research use only”) sellers. Evidence for elecoglipron comes from AstraZeneca’s own published and presented clinical trial data. As an oral small molecule rather than an injectable peptide, it is not the ... <a title="Berobenatide" class="read-more" href="https://peptideblog.net/peptides/berobenatide/" aria-label="Read more about Berobenatide">Read more</a>
-
Eloralintide
Eloralintide is an investigational Lilly amylin receptor agonist that produced up to 20.1 percent weight loss at 48 weeks in a 263 person phase 2 trial, under an efficacy estimand rather than a treatment policy one. Its selling point is receptor selectivity meant to reduce nausea, yet phase 2 reported nausea in 64 percent of the 6 mg arm, at or above the compound it was designed to improve on. It is not approved anywhere and no phase 3 study has reported.
-
Enicepatide (CT-388)
Enicepatide (CT-388) is Roche's investigational dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes. An early phase 1 extension showed 18.8% weight loss; phase 2 data showed 22.5% weight loss in obesity and a 2.65-point HbA1c drop in diabetes at the top dose. Not approved anywhere; phase 3 is recruiting, and Roche has named it its lead obesity asset.
-
Liraglutide
Liraglutide is an FDA-approved, once-daily GLP-1 receptor agonist sold as Victoza (type 2 diabetes, 2010) and Saxenda (chronic weight management, 2014). It produces about 8 percent weight loss at its approved dose, less than newer once-weekly drugs, but has one of the longest safety track records in its class.
-
LY4086940
LY4086940, listed by Eli Lilly under the program name GGG Tri-Agonist III, is an investigational oral weight-loss drug. A 219-person phase 1 trial finished in August 2026 and a 460-person phase 2 trial is registered. Structure and doses are undisclosed; never approved.
-
MariTide (Maridebart Cafraglutide)
Investigational compound This compound is not approved for any use. Evidence for MariTide comes from Amgen’s own published and presented clinical trial data, not from independent human trials or vendor sources. MariTide (maridebart cafraglutide, development code AMG 133) is a once-monthly, self-injected antibody-peptide conjugate being developed by Amgen for weight management, with and without type ... <a title="Berobenatide" class="read-more" href="https://peptideblog.net/peptides/berobenatide/" aria-label="Read more about Berobenatide">Read more</a>
-
Mazdutide
Mazdutide is a dual GLP-1/glucagon receptor agonist approved in China for chronic weight management and type 2 diabetes, with phase 3 weight-loss results in the 12 to 19 percent range. It is not approved in the United States or Europe, and its evidence base is drawn entirely from Chinese trial populations so far.
-
NBIP-1968
NBIP-1968 is Neurocrine Biosciences' investigational GLP-1/GIP/glucagon triple agonist for obesity, just entering phase 1 single-ascending-dose testing in August 2026. Its differentiator is a planned future combination with NBIP-2118 aimed at preserving lean mass. No efficacy data exists yet; never approved.
-
Nisotirostide
Nisotirostide (LY3457263) is Eli Lilly's investigational NPY2 receptor agonist, a PYY analog developed as an add-on to GLP-1 drugs like semaglutide and tirzepatide rather than a standalone treatment. Its most advanced trial measures blood sugar control, not weight loss. Not approved anywhere.
-
Orforglipron
Orforglipron is an FDA-approved (April 2026, brand name Foundayo), once-daily oral GLP-1 receptor agonist that is a non-peptide small molecule rather than a peptide. Phase 3 trials showed about 12.4 percent weight loss in obesity and meaningful HbA1c reduction in type 2 diabetes.
-
Pemvidutide
Pemvidutide is an investigational once-weekly GLP-1/glucagon dual receptor agonist from Altimmune. It is in Phase 3 for MASH, has reported Phase 2 results in alcohol use disorder and obesity, and is not approved anywhere.
-
Petrelintide
Petrelintide (ZP8396) is Zealand Pharma and Roche's investigational amylin analog for weight management, now in phase 3. Phase 2 results reached up to 10.7% weight loss with mostly mild nausea. Not approved anywhere.
-
Pramlintide
Pramlintide is an FDA-approved amylin analogue (Symlin, 2005) used as an add-on to mealtime insulin in type 1 and type 2 diabetes. It carries a boxed warning for severe hypoglycemia when combined with insulin and produces modest HbA1c and weight benefits, well below what the modern GLP-1 drug class achieves.
-
Retatrutide
Retatrutide is an investigational triple receptor agonist that is not approved anywhere in the world and has no marketing application on file. Its most quoted weight loss figures come from an on-treatment analysis and from a selected extension subset, and every phase 3 obesity result in circulation is an unpublished press release. Testing of 18 samples sold as retatrutide found one that matched its label.
-
RGT-075
Quick answer: RGT-075 is an investigational, orally bioavailable, once-daily small-molecule GLP-1 receptor full agonist developed by Regor Therapeutics for obesity and type 2 diabetes. Unlike injectable peptide GLP-1 drugs (semaglutide, liraglutide), RGT-075 is a small synthetic molecule taken as a pill. In a Phase 2a trial, 125 mg once daily produced 5% placebo-adjusted weight loss ... <a title="Berobenatide" class="read-more" href="https://peptideblog.net/peptides/berobenatide/" aria-label="Read more about Berobenatide">Read more</a>
-
Semaglutide
Semaglutide is approved in the United States across six product configurations, from 2 mg weekly by injection up to 7.2 mg weekly on Wegovy HD, approved 19 March 2026, and up to 25 mg daily as a tablet. SELECT cut major adverse cardiovascular events by 20 percent, but its hierarchical testing failed at cardiovascular death, which makes the mortality findings nominal rather than confirmatory. FLOW, whose hierarchy held, is the statistically stronger trial and gets a fraction of the attention.
-
SLU-PP-332
Also relevant to longevity and mitochondrial research. SLU-PP-332 is a non-peptide, pan-ERR receptor agonist studied only in mice as an exercise mimetic. It has never been tested in humans, has no established human dose, and is not approved for any use.
* Also filed under: Longevity and mitochondrial
-
Survodutide
Survodutide is an investigational glucagon and GLP-1 receptor dual agonist, built on the glucagon backbone rather than the GLP-1 one, and it is not approved anywhere. Almost every figure quoted for it, including 16.6 percent, 18.7 percent and 83 percent, is a secondary analysis rather than the trial primary result. Its phase 3 adverse event discontinuation rate of roughly 24 to 25 percent is several times that of approved agents in the class.
-
TERN-601
Quick answer: TERN-601 was an investigational, once-daily oral small-molecule GLP-1 receptor agonist developed by Terns Pharmaceuticals for obesity. It reached Phase 2 testing and produced statistically significant weight loss (up to 4.6% placebo-adjusted at 12 weeks), but Terns discontinued the program in October 2025 after three participants developed liver enzyme elevations during the Phase 2 ... <a title="Berobenatide" class="read-more" href="https://peptideblog.net/peptides/berobenatide/" aria-label="Read more about Berobenatide">Read more</a>
-
Tesofensine
Tesofensine is not a peptide, and it is not approved anywhere, including Mexico, where a non binding committee opinion in 2023 was widely reported as an approval and the sponsor confirmed in November 2024 that the application had not been granted. It is a substituted phenyltropane stimulant blocking all three monoamine transporters, with roughly 50 times the dopamine transporter affinity of cocaine. Its pivotal weight loss trial carries a Lancet Expression of Concern, and its own authors published an admission that adverse events were under reported at every centre.
-
Tirzepatide
Tirzepatide is approved in the US as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and, since December 2024, obstructive sleep apnoea. SURMOUNT-5, the only head-to-head trial against another approved incretin, found roughly 48 percent more weight loss than semaglutide when both were dosed to maximum tolerated dose. Its own cardiovascular outcomes trial, SURPASS-CVOT, narrowly missed statistical superiority against an active comparator, a materially different result from semaglutide's placebo-controlled SELECT trial.
-
Tradipitant (NEREUS, VLY-686)
Tradipitant (NEREUS) is an oral NK-1 receptor antagonist, FDA approved for motion-induced vomiting and tested in Phase 3 for vomiting after a single 1 mg dose of semaglutide.
-
UBT251
UBT251 is a GLP-1, GIP and glucagon triple agonist from China's United Laboratories group, licensed outside Greater China to Novo Nordisk. Two phase 2 trials in Cell Metabolism reported 13.6% to 19.7% weight loss at 24 weeks, and phase 3 is under way in China. Not approved anywhere.
-
VK2735
VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP receptor agonist for obesity, tested as both a weekly injection and a daily tablet. Phase 2 data showed up to 14.7% weight loss injectable and 12.2% oral; a maintenance study preserved up to 97% of that loss on less frequent dosing. Not approved anywhere; phase 3 is underway.